Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial - Concepedia

Concepedia

Publication | Open Access

Avelumab (anti–PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial

DOI Full Paper Access

81

Citations

27

References

2019

Year

Hyun Cheol Chung, Hendrik-Tobias Arkenau, Jeeyun Lee, Sun Young Rha, Do-Youn Oh, Lucjan Wyrwicz, Yoon‐Koo Kang, Keun‐Wook Lee, Jeffrey R. Infante, Sung Sook Lee,

Journal for ImmunoTherapy of Cancer

Abstract

ClinicalTrials.gov NCT01772004 ; registered 21 January 2013.

References

	Year	Citations

Page 1